Check out Dr. Jillian Tsai discussing Palliative Radiotherapy for Metastatic and Oligometastatic Cancers - From Conventional to Stereotactic on #VuMedi tinyurl.com/yphh4tkx #NSCLC #LCSM #LungCancer #ASCO25

SCLC transformation from EGFR+ NSCLC, outcomes & tx? ESMO Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) Chiara CATANIA OncoAlert #LCSM esmoopen.com/article/S2059-…

Check out Dr. Javier Cortes discussing "ESMO Breast 2025 Summary: Sequencing ADCs to Overcome Resistance in mBC" on #VuMedi tinyurl.com/yo5b2n96 #TNBC #BCSM #BreastCancer #ASCO25

Check out Dr. discussing "ESR1 Mutation Prevalence in HR+/HER2- mBC: Detection Frequency in Liquid Biopsy" on #VuMedi tinyurl.com/yrmyt7o2 #HR+ #BCSM #BreastCancer #ASCO25

Check out Dr. Javier Cortes discussing "ESMO Breast 2025 Summary: Sequencing ADCs to Overcome Resistance in mBC" on #VuMedi tinyurl.com/yo5b2n96 #HR+ #BCSM #BreastCancer #ASCO25

Check out Dr. discussing "Transforming the Treatment Landscape for ER+/HER2- mBC With Oral SERDs" on #VuMedi tinyurl.com/ylxzkl5r #HR+ #BCSM #BreastCancer #ASCO25

Check out Dr. Abirami Sivapiragasam discussing "ASCO® & ESMO Breast 2025 Insights: Prognostic Value of Oncotype and MammaPrint Across Diverse Breast Cancer Populations - An NCD..." on #VuMedi tinyurl.com/yuwqhyx6 #HR+ #BCSM #BreastCancer #ASCO25

ASCO® 2025 Summary: Best of Myeloma-Key Trials & Clinical Insights | VuMedi vumedi.com/video/ascor-20… @vumedi ➡️Highlights, Summary, Take Home Messages ➡️Practice Changing vs Practice Informing ASCO OncoDaily Multiple Myeloma Hub @MSKCancerCente ASH Clinical News #MedTwitter #MedEd #ASCO25

🫁 Eight ASCO Ecucational Books on Lung Cancer have been published. 🫁

📺I briefly summarized the second line treatment of biliary tract cancers 🔵Thanks VuMedi for the kind invitation! 🔵Link for the video recording (25th June) 👇 vumedi.com/video/advancin… VuMedi Oncology OncoAlert #Cancer #Oncology #MedX #biliary #cholangiocarcinoma

vumedi.com/video/hematolo… #blood #MedTwitter #podcast #Meeting #GlobalGoals ISTH ATHN ASH European Hematology Association Hope for Hemophilia GreatLakesHemophilia Bleeding Disorders Foundation of Florida Hemophilia Ontario HemophiliaMB National Organization for Rare Disorders (NORD) TED Talks World Health Organization (WHO) BloodStream Media Scripps Research Deloitte Life Sciences & Health Care

Therapy for Stage IV NSCLC With (1) & Without (2) Driver Alterations: ASCO Living Guideline, Version 2025.1 1⃣ ascopubs.org/doi/pdf/10.120… 2⃣ ascopubs.org/doi/pdf/10.120…

🔥🚨Hot Off the Press #BigNews Press Release by AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in

You need some data as to how to use dato? Below guide offers a practical way to use Datroway in your clinic! ☑️mucositis ☑️pneumonitis ☑️ocular tox Now that Dato-dxd is approved for both breast and EGFR-mutated NSCLC indications, implementation of best practices is key! 👀

🎥 Watch my VuMedi talk on selinexor in relapsed/refractory multiple myeloma I cover: ✅ Key data from STORM, BOSTON, STOMP ✅ Use in high-risk disease (del17p, EMD) ✅ Bridging to CAR-T ✅ Side effect management tips that actually work 📍 vumedi.com/video/selinexo…

🫁 Tumour–microenvironment crosstalk in #NSCLC drives resistance, metastasis, and outcomes. Understanding spatial niches, inflammation, and immune evasion can reshape treatment strategies. 📖 NatureRevClinOncol 👉 doi.org/10.1038/s41571… #CánCare #immunotherapy #biomarkers

Recorded a small talk for VuMedi Oncology on early onset colon cancer 🔗 vumedi.com/video/comparin… Key points I covered: 🔹 evolving trends in early (<50) and very early onset (<40) colon cancer 🔹 Stage-wise survival differences 🔹 Implications for screening and awareness

Overview of 1L Treatment Landscape in Advanced BTC | VuMedi vumedi.com/video/overview… via @vumedi City of Hope Cholangiocarcinoma Foundation #btc #cholangiocarcinoma

Check out Dr. Christian Singer discussing ASCO® 2025 Insights: ABCSG 45 Trial - Neoadjuvant Olaparib/Carboplatin vs. Docetaxel/Epirubicin/Cyclophosphamide (TAC) in HRD-Po... on #VuMedi tinyurl.com/25w6xyed #HR+ #BCSM #BreastCancer #ASCO25

Check out Dr. Chiara Molinelli discussing The Journey of Patients Affected by HR+/HER2- mBC From CDK 4/6i to 2L Treatment: A Real-World Analysis of 701 Patients Enrolled ... on #VuMedi tinyurl.com/2736hwpd #HR+ #BCSM #BreastCancer #ASCO25